Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells

@article{Stenner2008EffectsON,
  title={Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells},
  author={Max-Philipp Stenner and Anne Waschbisch and Dorothea Buck and Sebastian Doerck and Hermann Einsele and K. V. Toyka and Heinz S. Wiendl},
  journal={PLoS ONE},
  year={2008},
  volume={3},
  pages={15 - 23}
}
BACKGROUND Natalizumab, a monoclonal humanized antibody targeting the alpha-4 chain of very late activation antigen 4 (VLA-4) exerts impressive therapeutic effects in patients with relapsing-remitting multiple sclerosis. Our objective was to study impacts of Natalizumab therapy on Foxp3+ T regulatory cells (Tregs) in multiple sclerosis (MS) patients. METHODOLOGY A combined approach of in vitro and ex vivo experiments using T cells isolated from the peripheral blood of healthy donors and… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Natalizumab for multiple sclerosis.

  • The New England journal of medicine
  • 2007
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Effects of cryopreservation on CD4+ CD25+ T cells of HIV-1 infected individuals

AC Seale, BC de Jong, I Zaidi, M Duvall, H Whittle
  • J Clin Lab Anal
  • 2008
VIEW 2 EXCERPTS